Plus Therapeutics Inc (NASDAQ: PSTV) on Tuesday, plunged -7.72% from the previous trading day, before settling in for the closing price of $0.59. Within the past 52 weeks, PSTV’s price has moved between $0.16 and $2.31.
A company in the Healthcare sector has jumped its sales by 46.51% annually for the last half of the decade. The company achieved an average annual earnings per share of 87.69%. With a float of $136.95 million, this company’s outstanding shares have now reached $137.43 million.
In an organization with 21 employees, it is important to assess its efficiency.
Plus Therapeutics Inc (PSTV) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Plus Therapeutics Inc is 0.35%, while institutional ownership is 4.89%. The most recent insider transaction that took place on Nov 04 ’25, was worth 10,200. In this transaction Chief Financial Officer of this company bought 20,000 shares at a rate of $0.51, taking the stock ownership to the 68,138 shares. Before that another transaction happened on Aug 22 ’25, when Company’s Director bought 110,000 for $0.49, making the entire transaction worth $53,779. This insider now owns 139,327 shares in total.
Plus Therapeutics Inc (PSTV) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.49 earnings per share (EPS) for the period topping the consensus outlook (set at -0.5) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.04% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Plus Therapeutics Inc (PSTV) is currently performing well based on its current performance indicators. A quick ratio of 1.27 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Let’s dig in a bit further. During the last 5-days, its volume was 4.45 million. That was inferior than the volume of 18.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.97%.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 29.69%, which indicates a significant increase from 7.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0584 in the past 14 days, which was lower than the 0.0663 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5839, while its 200-day Moving Average is $0.5783. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.5801. Second resistance stands at $0.6112. The third major resistance level sits at $0.6325. If the price goes on to break the first support level at $0.5277, it is likely to go to the next support level at $0.5064. The third support level lies at $0.4753 if the price breaches the second support level.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
Market capitalization of the company is 75.43 million based on 137,429K outstanding shares. Right now, sales total 5,820 K and income totals -12,980 K. The company made 1,400 K in profit during its latest quarter, and -4,420 K in sales during its previous quarter.
